The genetics of dyskeratosis congenita

Cancer Genetics

Volumn 204, Issue 12, 2011, Pages 635-645

  Mason, Philip J ^a   Bessler, Monica ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anticipation; Bone marrow failure; Dyskerin; Short telomeres; Telomerase

Indexed keywords

C16ORF57 GENE; CANCER INCIDENCE; CLINICAL FEATURE; DKC1 GENE; DYSKERATOSIS CONGENITA; GENE EXPRESSION; GENE MAPPING; GENETIC ASSOCIATION; HUMAN; LINKAGE ANALYSIS; MUTATIONAL ANALYSIS; MUTATOR GENE; NHP2 GENE; NONHUMAN; NOP10 GENE; PRIORITY JOURNAL; REVIEW; TCAB1 GENE; TERC GENE; TERT GENE; TINF2 GENE; BIOLOGICAL MODEL; GENETICS; PATHOLOGY; X CHROMOSOMAL INHERITANCE;

CELL CYCLE PROTEIN; DKC1 PROTEIN, HUMAN; NHP2 PROTEIN, HUMAN; NOP10 PROTEIN, HUMAN; NUCLEAR PROTEIN; RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; SMALL NUCLEOLAR RIBONUCLEOPROTEIN; TELOMERASE; TELOMERASE CAJAL BODY PROTEIN 1, HUMAN; TELOMERASE RNA; TELOMERE BINDING PROTEIN; TERT PROTEIN, HUMAN; TINF2 PROTEIN, HUMAN;

CELL CYCLE PROTEINS; DYSKERATOSIS CONGENITA; GENES, X-LINKED; HUMANS; MODELS, GENETIC; NUCLEAR PROTEINS; RIBONUCLEOPROTEINS, SMALL NUCLEAR; RIBONUCLEOPROTEINS, SMALL NUCLEOLAR; RNA; TELOMERASE; TELOMERE-BINDING PROTEINS;

EID: 84858791727     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.11.002     Document Type: Review

References (113)

1. Zinsser F. Atrophia cutis reticularis pigmentione, dystrophia unguium et leukoplakia oris (poikilodermia atrophicans vascularis Jacobi). Ikonogr Derm (Kyoto) 1906, 5:219-223.
2. Engman M.A. A unique case of reticular pigmentation of the skin with atrophy. Arch Derm Syph Suppl 1926, 13:685-687.
3. Cole H., Rauschkolb J., Toomey J. Dyskeratosis congenita with pigmentation, dystrophia unguis and leukokeratosis oris. Arch Derm Syph Suppl 1930, 21:71-95.
4. Drachtman R.A., Alter B.P. Dyskeratosis congenita. Dermatol Clin 1995, 13:33-39.
5. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000, 110:768-779.
6. Vulliamy T.J., Marrone A., Knight S.W., et al. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006, 107:2680-2685.
7. Savage S.A., Alter B.P. Dyskeratosis congenita. Hematol Oncol Clin North Am 2009, 23:215-231.
8. Knight S.W., Vulliamy T.J., Heiss N.S., et al. 1.4 Mb candidate gene region for X linked dyskeratosis congenita defined by combined haplotype and X chromosome inactivation analysis. J Med Genet 1998, 35:993-996.
9. Heiss N.S., Knight S.W., Vulliamy T.J., et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998, 19:32-38.
10. Meier U.T., Blobel G. NAP57, a mammalian nucleolar protein with a putative homolog in yeast and bacteria. J Cell Biol 1994, 127:1505-1514.
11. Meier U.T. The many facets of H/ACA ribonucleoproteins. Chromosoma 2005, 114:1-14.
12. Kiss T., Fayet-Lebaron E., Jady B.E. Box H/ACA small ribonucleoproteins. Mol Cell 2010, 37:597-606.
13. Watkins N.J., Gottschalk A., Neubauer G., et al. Cbf5p, a potential pseudouridine synthase, and Nhp2p, a putative RNA-binding protein, are present together with Gar1p in all H BOX/ACA-motif snoRNPs and constitute a common bipartite structure. RNA 1998, 4:1549-1568.
14. Lafontaine D.L., Bousquet-Antonelli C., Henry Y., et al. The box H + ACA snoRNAs carry Cbf5p, the putative rRNA pseudouridine synthase. Genes Dev 1998, 12:527-537.
15. Cadwell C., Yoon H.J., Zebarjadian Y., et al. The yeast nucleolar protein Cbf5p is involved in rRNA biosynthesis and interacts genetically with the RNA polymerase I transcription factor RRN3. Mol Cell Biol 1997, 17:6175-6183.
16. Reichow S.L., Hamma T., Ferre-D'Amare A.R., et al. The structure and function of small nucleolar ribonucleoproteins. Nucleic Acids Res 2007, 35:1452-1464.
17. Mitchell J.R., Wood E., Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999, 402:551-555.
18. Mitchell J.R., Cheng J., Collins K. A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3' end. Mol Cell Biol 1999, 19:567-576.
19. Venteicher A.S., Abreu E.B., Meng Z., et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 2009, 323:644-648.
20. Fu D., Collins K. Human telomerase and Cajal body ribonucleoproteins share a unique specificity of Sm protein association. Genes Dev 2006, 20:531-536.
21. Jady B.E., Bertrand E., Kiss T. Human telomerase RNA and box H/ACA scaRNAs share a common Cajal body-specific localization signal. J Cell Biol 2004, 164:647-652.
22. Theimer C.A., Jady B.E., Chim N., et al. Structural and functional characterization of human telomerase RNA processing and cajal body localization signals. Mol Cell 2007, 27:869-881.
23. Darzacq X., Jady B.E., Verheggen C., et al. Cajal body-specific small nuclear RNAs: a novel class of 2'-O-methylation and pseudouridylation guide RNAs. EMBO J 2002, 21:2746-2756.
24. Wong J.M., Collins K. Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev 2006, 20:2848-2858.
25. Wong J.M., Kyasa M.J., Hutchins L., et al. Telomerase RNA deficiency in peripheral blood mononuclear cells in X-linked dyskeratosis congenita. Hum Genet 2004, 115:448-455.
26. Mochizuki Y., He J., Kulkarni S., et al. Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc Natl Acad Sci U S A 2004, 101:10756-10761.
27. Gu B.W., Bessler M., Mason P.J. A pathogenic dyskerin mutation impairs proliferation and activates a DNA damage response independent of telomere length in mice. Proc Natl Acad Sci U S A 2008, 105:10173-10178.
28. Cohen S.B., Graham M.E., Lovrecz G.O., et al. Protein composition of catalytically active human telomerase from immortal cells. Science 2007, 315:1850-1853.
29. Bellodi C., Kopmar N., Ruggero D. Deregulation of oncogene-induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO J 2010, 29:1865-1876.
30. Yoon A., Peng G., Brandenburger Y., et al. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 2006, 312:902-906.
31. Ruggero D., Grisendi S., Piazza F., et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003, 299:259-262.
32. Bessler M., Mason P., Link D., et al. Inherited bone marrow failure syndromes. Nathan and Oski's Hematology of Infancy and Childhood 2008, 307-395. Saunders, Philadelphia. S. Orkin, D. Nathan, D. Ginsburg, A. Look, D. Fisher, S. Lux (Eds.).
33. Hoyeraal H.M., Lamvik J., Moe P.J. Congenital hypoplastic thrombocytopenia and cerebral malformations in two brothers. Acta Paediatr Scand 1970, 59:185-191.
34. Hreidarsson S., Kristjansson K., Johannesson G., et al. A syndrome of progressive pancytopenia with microcephaly, cerebellar hypoplasia and growth failure. Acta Paediatr Scand 1988, 77:773-775.
35. Knight S.W., Heiss N.S., Vulliamy T.J., et al. Unexplained aplastic anaemia, immunodeficiency, and cerebellar hypoplasia (Hoyeraal-Hreidarsson syndrome) due to mutations in the dyskeratosis congenita gene, DKC1. Br J Haematol 1999, 107:335-339.
36. Knight S.W., Heiss N.S., Vulliamy T.J., et al. X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Hum Genet 1999, 65:50-58.
37. Rashid R., Liang B., Baker D.L., et al. Crystal structure of a Cbf5-Nop10-Gar1 complex and implications in RNA-guided pseudouridylation and dyskeratosis congenita. Mol Cell 2006, 21:249-260.
38. Li L., Ye K. Crystal structure of an H/ACA box ribonucleoprotein particle. Nature 2006, 443:302-307.
39. Hamma T., Reichow S.L., Varani G., et al. The Cbf5-Nop10 complex is a molecular bracket that organizes box H/ACA RNPs. Nat Struct Mol Biol 2005, 12:1101-1107.
40. Vulliamy T.J., Knight S.W., Heiss N.S., et al. Dyskeratosis congenita caused by a 3' deletion: germline and somatic mosaicism in a female carrier. Blood 1999, 94:1254-1260.
41. Knight S.W., Vulliamy T.J., Morgan B., et al. Identification of novel DKC1 mutations in patients with dyskeratosis congenita: implications for pathophysiology and diagnosis. Hum Genet 2001, 108:299-303.
42. Vulliamy T., Marrone A., Goldman F., et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001, 413:432-435.
43. Blackburn E.H., Collins K. Telomerase: an RNP enzyme synthesizes DNA. Cold Spring Harb Perspect Biol 2011, 3.
44. Autexier C., Lue N.F. The structure and function of telomerase reverse transcriptase. Annu Rev Biochem 2006, 75:493-517.
45. Wright W.E., Piatyszek M.A., Rainey W.E., et al. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996, 18:173-179.
46. Kim N.W., Piatyszek M.A., Prowse K.R., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
47. Artandi S.E., DePinho R.A. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 2000, 10:39-46.
48. Field J.J., Mason P.J., An P., et al. Low frequency of telomerase RNA mutations among children with aplastic anemia or myelodysplastic syndrome. J Pediatr Hematol Oncol 2006, 28:450-453.
49. Vulliamy T., Marrone A., Szydlo R., et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 2004, 36:447-449.
50. Ball S.E., Gibson F.M., Rizzo S., et al. Progressive telomere shortening in aplastic anemia. Blood 1998, 91:3582-3892.
51. Vulliamy T., Marrone A., Dokal I., et al. Association between aplastic anaemia and mutations in telomerase RNA. Lancet 2002, 359:2168-2170.
52. Fogarty P.F., Yamaguchi H., Wiestner A., et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 2003, 362:1628-1630.
53. Yamaguchi H., Baerlocher G.M., Lansdorp P.M., et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 2003, 102:916-918.
54. Goldman F., Bouarich R., Kulkarni S., et al. The effect of TERC haploinsufficiency on the inheritance of telomere length. Proc Natl Acad Sci U S A 2005, 102:17119-17124.
55. Armanios M., Chen J.L., Chang Y.P., et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A 2005, 102:15960-15964.
56. Blasco M.A., Lee H.W., Hande M.P., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91:25-34.
57. Hao L.Y., Armanios M., Strong M.A., et al. Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 2005, 123:1121-1131.
58. Armanios M., Alder J.K., Parry E.M., et al. Short telomeres are sufficient to cause the degenerative defects associated with aging. Am J Hum Genet 2009, 85:823-832.
59. Chen J.L., Greider C.W. Telomerase RNA structure and function: implications for dyskeratosis congenita. Trends Biochem Sci 2004, 29:183-192.
60. Fu D., Collins K. Distinct biogenesis pathways for human telomerase RNA and H/ACA small nucleolar RNAs. Mol Cell 2003, 11:1361-1372.
61. Ly H., Calado R.T., Allard P., et al. Functional characterization of telomerase RNA variants found in patients with hematological disorders. Blood 2005, 105:2331-2339.
62. Marrone A., Stevens D., Vulliamy T., et al. Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency. Blood 2004, 104:3936-3942.
63. Beattie T.L., Zhou W., Robinson M.O., et al. Functional multimerization of the human telomerase reverse transcriptase. Mol Cell Biol 2001, 21:6151-6160.
64. Wenz C., Enenkel B., Amacker M., et al. Human telomerase contains two cooperating telomerase RNA molecules. EMBO J 2001, 20:3526-3534.
65. Marrone A., Sokhal P., Walne A., et al. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. Haematologica 2007, 92:1013-1020.
66. Comolli L.R., Smirnov I., Xu L., et al. A molecular switch underlies a human telomerase disease. Proc Natl Acad Sci U S A 2002, 99:16998-17003.
67. Ly H., Xu L., Rivera M.A., et al. A role for a novel 'trans-pseudoknot' RNA-RNA interaction in the functional dimerization of human telomerase. Genes Dev 2003, 17:1078-1083.
68. Vulliamy T., Walne A., Baskaradas A., et al. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis 2005, 34:257-263.
69. Yamaguchi H., Calado R.T., Ly H., et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005, 352:1413-1424.
70. Du H.Y., Idol R., Robledo S., et al. Telomerase reverse transcriptase haploinsufficiency and telomere length in individuals with 5p- syndrome. Aging Cell 2007, 6:689-697.
71. Armanios M.Y., Chen J.J., Cogan J.D., et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007, 356:1317-1326.
72. Tsakiri K.D., Cronkhite J.T., Kuan P.J., et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 2007, 104:7552-7557.
73. Calado R.T., Regal J.A., Kleiner D.E., et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One 2009, 4:e7926.
74. Calado R.T., Regal J.A., Hills M., et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A 2009, 106:1187-1192.
75. Calado R.T., Brudno J., Mehta P., et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology 2011, 53:1600-1607.
76. Walne A.J., Vulliamy T., Marrone A., et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet 2007, 16:1619-1629.
77. Vulliamy T., Beswick R., Kirwan M., et al. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc Natl Acad Sci U S A 2008, 105:8073-8078.
78. Trahan C., Martel C., Dragon F. Effects of dyskeratosis congenita mutations in dyskerin, NHP2 and NOP10 on assembly of H/ACA pre-RNPs. Hum Mol Genet 2010, 19:825-836.
79. Grozdanov P.N., Roy S., Kittur N., et al. SHQ1 is required prior to NAF1 for assembly of H/ACA small nucleolar and telomerase RNPs. RNA 2009, 15:1188-1197.
80. Leulliot N., Godin K.S., Hoareau-Aveilla C., et al. The box H/ACA RNP assembly factor Naf1p contains a domain homologous to Gar1p mediating its interaction with Cbf5p. J Mol Biol 2007, 371:1338-1353.
81. Fatica A., Dlakic M., Tollervey D. Naf1 p is a box H/ACA snoRNP assembly factor. RNA 2002, 8:1502-1514.
82. Savage S.A., Giri N., Baerlocher G.M., et al. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 2008, 82:501-509.
83. Riyaz A., Riyaz N., Jayakrishnan M.P., et al. Revesz syndrome. Indian J Pediatr 2007, 74:862-863.
84. Walne A.J., Vulliamy T., Beswick R., et al. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 2008, 112:3594-3600.
85. Du H.Y., Mason P.J., Bessler M., et al. TINF2 mutations in children with severe aplastic anemia. Pediatr Blood Cancer 2009, 52:687.
86. Sasa G., Ribes-Zamora A., Nelson N., et al. Three novel truncating TINF2 mutations causing severe dyskeratosis congenita in early childhood. Clin Genet 2011, 10.1111/j.1399-0004.2011.01658.x.
87. Palm W., de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet 2008, 42:301-334.
88. Abreu E., Aritonovska E., Reichenbach P., et al. TIN2-tethered TPP1 recruits human telomerase to telomeres in vivo. Mol Cell Biol 2010, 30:2971-2982.
89. Yang D., He Q., Kim H., et al. TIN2 protein dyskeratosis congenita missense mutants are defective in association with telomerase. J Biol Chem 2011, 286:23022-23030.
90. Canudas S., Houghtaling B.R., Bhanot M., et al. A role for heterochromatin protein 1{gamma} at human telomeres. Genes Dev 2011, 25:1807-1819.
91. Liu L., Bailey S.M., Okuka M., et al. Telomere lengthening early in development. Nat Cell Biol 2007, 9:1436-1441.
92. Zalzman M., Falco G., Sharova L.V., et al. Zscan4 regulates telomere elongation and genomic stability in ES cells. Nature 2010, 464:858-863.
93. Zhong F., Savage S.A., Shkreli M., et al. Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita. Genes Dev 2011, 25:11-16.
94. Tycowski K.T., Shu M.D., Kukoyi A., et al. A conserved WD40 protein binds the Cajal body localization signal of scaRNP particles. Mol Cell 2009, 34:47-57.
95. Mahmoudi S., Henriksson S., Corcoran M., et al. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell 2009, 33:462-471.
96. Jady B.E., Richard P., Bertrand E., et al. Cell cycle-dependent recruitment of telomerase RNA and Cajal bodies to human telomeres. Mol Biol Cell 2006, 17:944-954.
97. Walne A.J., Vulliamy T., Beswick R., et al. Mutations in C16orf57 and normal-length telomeres unify a subset of patients with dyskeratosis congenita, poikiloderma with neutropenia and Rothmund-Thomson syndrome. Hum Mol Genet 2010, 19:4453-4461.
98. Volpi L., Roversi G., Colombo E.A., et al. Targeted next-generation sequencing appoints c16orf57 as clericuzio-type poikiloderma with neutropenia gene. Am J Hum Genet 2010, 86:72-76.
99. Lamm N., Ordan E., Shponkin R., et al. Diminished telomeric 3' overhangs are associated with telomere dysfunction in Hoyeraal-Hreidarsson syndrome. PLoS One 2009, 4:e5666.
100. Alter B.P., Giri N., Savage S.A., et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010, 150:179-188.
101. Alter B.P., Giri N., Savage S.A., et al. Cancer in dyskeratosis congenita. Blood 2009, 113:6549-6557.
102. Vulliamy T.J., Kirwan M.J., Beswick R., et al. Differences in disease severity but similar telomere lengths in genetic subgroups of patients with telomerase and shelterin mutations. PLoS One 2011, 6:e24383.
103. Artandi S.E., DePinho R.A. Telomeres and telomerase in cancer. Carcinogenesis 2010, 31:9-18.
104. Cesare A.J., Reddel R.R. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 2010, 11:319-330.
105. Dietz A.C., Orchard P.J., Baker K.S., et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant 2011, 46:98-104.
106. Alter B.P., Baerlocher G.M., Savage S.A., et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 2007, 110:1439-1447.
107. Du H.Y., Pumbo E., Ivanovich J., et al. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 2009, 113:309-316.
108. Epel E.S., Blackburn E.H., Lin J., et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A 2004, 101:17312-17315.
109. Nelson N.D., Bertuch A.A. Dyskeratosis congenita as a disorder of telomere maintenance. Mutat Res 2011.
110. Savage S.A., Dokal I., Armanios M., et al. Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer 2009, 53:520-523.
111. Dokal I., Vulliamy T., Mason P., et al. Clinical utility gene card for: Dyskeratosis congenita. Eur J Hum Genet 2011, 19. 10.1038/ejhg.2011.90.
112. Egan E.D., Collins K. Specificity and stoichiometry of subunit interactions in the human telomerase holoenzyme assembled in vivo. Mol Cell Biol 2010, 30:2775-2786.
113. Zhang Q., Kim N.K., Feigon J. Architecture of human telomerase RNA. Proc Natl Acad Sci USA 2011, 108:20325-20332.